EpiEndo Pharmaceuticals is on the rise. The company has recently secured next phase financing and been awarded several prestigious awards, and is on course to potentially change the treatment paradigm for chronic obstructive pulmonary disease.
At the Swedish-American Life Science Summit (SALSS) 2